Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Strattera Medicaid Reimbursement In 42 States; Launch Beats Lexapro

Executive Summary

Lilly's Strattera has gained Medicaid reimbursement in 42 states in the three months since the launch of the attention deficit disorder drug, Investor Relations Manager Craig Hartman told investors April 22

You may also be interested in...



Lilly Remains Attentive To Corporate Affairs; Strattera Head Nobles Named VP

Lilly Strattera Product Team Leader Anne Nobles will focus her attention on public policy and communications issues as the firm's new VP-corporate affairs, effective June 1

Lilly Remains Attentive To Corporate Affairs; Strattera Head Nobles Named VP

Lilly Strattera Product Team Leader Anne Nobles will focus her attention on public policy and communications issues as the firm's new VP-corporate affairs, effective June 1

Lilly Strattera Disease Awareness Campaign Will Focus On Adult ADHD

Lilly is designing a disease awareness campaign targeting adults for its attention deficit and hyperactivity disorder product Strattera

Related Content

UsernamePublicRestriction

Register

PS041698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel